📊 SMMT Key Takeaways
Is Summit Therapeutics Inc. (SMMT) a Good Investment?
Summit Therapeutics has zero revenue with a -$1.1B operating loss and -$323.6M free cash flow burn, indicating an early-stage or failed commercialization biotech with limited cash runway (~9 months at current burn). While the balance sheet shows strong liquidity and no debt, the company is entirely dependent on unproven pipeline assets with no commercial validation, making this a highly speculative bet with imminent funding pressure.
Why Buy Summit Therapeutics Inc. Stock? SMMT Key Strengths
- Strong liquidity position with 9.87x current ratio and $225.3M cash reserves
- Clean balance sheet with no long-term debt and positive $658.9M stockholders' equity
- Reasonable asset base of $751.2M providing some financial cushion
SMMT Stock Risks: Summit Therapeutics Inc. Investment Risks
- Zero revenue indicates no commercial product success or market adoption
- Annual burn rate of -$322.9M operating cash flow with only ~9 months of cash runway remaining
- Massive -$1.1B operating loss signals either failed clinical programs or pre-commercialization R&D spending
- Complete dependence on pipeline clinical trial success with no revenue-generating assets
- No insider buying activity in last 90 days suggests limited management confidence
- Imminent dilution or financing needs likely within 12 months
Key Metrics to Watch
- Cash balance and monthly burn rate to assess runway extension
- Pipeline clinical trial progress and regulatory milestones for any approved products
- Operating cash flow trends and any revenue inflection from commercialization efforts
Summit Therapeutics Inc. (SMMT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.87x current ratio provides a solid financial cushion.
SMMT Profit Margin, ROE & Profitability Analysis
SMMT vs Healthcare Sector: How Summit Therapeutics Inc. Compares
How Summit Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Summit Therapeutics Inc. Stock Overvalued? SMMT Valuation Analysis 2026
Based on fundamental analysis, Summit Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Summit Therapeutics Inc. Balance Sheet: SMMT Debt, Cash & Liquidity
SMMT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Summit Therapeutics Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-0.99 indicates the company is currently unprofitable.
SMMT Revenue Growth, EPS Growth & YoY Performance
SMMT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$21.3M | $-0.03 |
| Q3 2023 | N/A | -$21.3M | $-0.03 |
| Q2 2023 | N/A | -$14.7M | $-0.02 |
| Q1 2023 | N/A | -$21.4M | $-0.15 |
| Q3 2022 | $220.0K | -$19.6M | $-0.14 |
| Q2 2022 | $57.0K | -$16.8M | $-0.17 |
| Q1 2022 | $192.0K | -$17.5M | $-0.21 |
| Q3 2021 | $181.0K | -$17.7M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Summit Therapeutics Inc. Dividends, Buybacks & Capital Allocation
SMMT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Summit Therapeutics Inc. (CIK: 0001599298)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SMMT
What is the AI rating for SMMT?
Summit Therapeutics Inc. (SMMT) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SMMT's key strengths?
Claude: Strong liquidity position with 9.87x current ratio and $225.3M cash reserves. Clean balance sheet with no long-term debt and positive $658.9M stockholders' equity.
What are the risks of investing in SMMT?
Claude: Zero revenue indicates no commercial product success or market adoption. Annual burn rate of -$322.9M operating cash flow with only ~9 months of cash runway remaining.
What is SMMT's revenue and growth?
Summit Therapeutics Inc. reported revenue of $0.0.
Does SMMT pay dividends?
Summit Therapeutics Inc. does not currently pay dividends.
Where can I find SMMT SEC filings?
Official SEC filings for Summit Therapeutics Inc. (CIK: 0001599298) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SMMT's EPS?
Summit Therapeutics Inc. has a diluted EPS of $-1.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SMMT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Summit Therapeutics Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SMMT stock overvalued or undervalued?
Valuation metrics for SMMT: ROE of -163.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SMMT stock in 2026?
Our dual AI analysis gives Summit Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SMMT's free cash flow?
Summit Therapeutics Inc.'s operating cash flow is $-322.9M, with capital expenditures of $657.0K.
How does SMMT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -163.9% (avg: 15%), current ratio 9.87 (avg: 2).